{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:31:14Z","timestamp":1792794674176,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA229739"],"award-info":[{"award-number":["1R01CA229739"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["130421-RSG-17-071-01-TBG"],"award-info":[{"award-number":["130421-RSG-17-071-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hepatoblastoma is the most common pediatric liver cancer, with the fastest rising incidence among childhood malignancies. Early genomic studies revealed that hepatoblastoma has the lowest mutational burden of any human cancer, however, recent advances in single-cell RNA-seq, multiomics, spatial transcriptomics, and functional genomics screenings have revealed substantial complexity. Diverse cellular subpopulations, divergent WNT signaling, key developmental pathways, and intricate interactions between the tumor cells and tumor immune microenvironment (TME) collectively shape tumor heterogeneity, disease progression, therapeutic responses, and genetic dependencies. Mosaic embryonic loss of heterozygosity (LOH) at chromosome 11p15.5 may be a hepatoblastoma-initiating event, as clonal expansion of 11p15.5 LOH occurs in adjacent normal liver tissue. A cholangiocyte-like subpopulation expresses <jats:italic>FGF19<\/jats:italic>, in a <jats:italic>SOX4-<\/jats:italic>dependent, paracrine manner, to drive the proliferation of neighboring embryonal hepatoblastoma cells. WNT-signaling dependent MDK promotes the immunosuppressive TME, which impairs immune cell infiltration. The TME may also be driven by islands of erythroblasts, which influence treatment resistance. Plasticity driven by changes in chromatin accessibility enables differentiation transition between hepatocytic and liver progenitor cell types, which is associated with treatment resistance. Here, we review recent findings in pediatric hepatoblastoma cells, tumor-associated cell types, and genetic dependencies that will serve to advance hepatoblastoma therapy.<\/jats:p>\n          <jats:p>\n            <jats:bold>Clinical trial number<\/jats:bold>: Not applicable.<\/jats:p>","DOI":"10.1186\/s12943-025-02405-8","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T04:49:08Z","timestamp":1752900548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["From preneoplastic lesion to heterogenous tumor: recent insights into hepatoblastoma biology and therapeutic opportunities"],"prefix":"10.1186","volume":"24","author":[{"given":"Jun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Davidoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"2405_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1093526619875228","volume":"23","author":"S Ranganathan","year":"2020","unstructured":"Ranganathan S, Lopez-Terrada D, Alaggio R. Hepatoblastoma and pediatric hepatocellular carcinoma: an update. Pediatr Dev Pathol. 2020;23:79\u201395. https:\/\/doi.org\/10.1177\/1093526619875228","journal-title":"Pediatr Dev Pathol"},{"key":"2405_CR2","doi-asserted-by":"publisher","first-page":"pkz007","DOI":"10.1093\/jncics\/pkz007","volume":"3","author":"AK Hubbard","year":"2019","unstructured":"Hubbard AK, Spector LG, Fortuna G, Marcotte EL, Poynter JN. Trends in international incidence of pediatric cancers in children under 5 years of age: 1988\u20132012. JNCI Cancer Spectr. 2019;3:pkz007. https:\/\/doi.org\/10.1093\/jncics\/pkz007","journal-title":"JNCI Cancer Spectr"},{"key":"2405_CR3","doi-asserted-by":"publisher","first-page":"e2148013","DOI":"10.1001\/jamanetworkopen.2021.48013","volume":"5","author":"S Zhou","year":"2022","unstructured":"Zhou S, Malvar J, Chi YY, Stein J, Wang L, Genyk Y, Sposto R, Mascarenhas L. Independent assessment of the children\u2019s hepatic tumors international collaboration risk stratification for hepatoblastoma and the association of tumor histological characteristics with prognosis. JAMA Netw Open. 2022;5:e2148013. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.48013","journal-title":"JAMA Netw Open"},{"key":"2405_CR4","doi-asserted-by":"publisher","unstructured":"Dembowska-Baginska B, Wieckowska J, Brozyna A, Swieszkowska E, Ismail H, Broniszczak-Czyszek D, Stefanowicz M, Grajkowska W, Kalicinski P. Health status in Long-Term survivors of hepatoblastoma. Cancers (Basel). 2019;11. https:\/\/doi.org\/10.3390\/cancers11111777","DOI":"10.3390\/cancers11111777"},{"key":"2405_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.09.026","volume":"141","author":"S Cairo","year":"2020","unstructured":"Cairo S, Armengol C, Maibach R, Haberle B, Becker K, Carrillo-Reixach J, Guettier C, Vokuhl C, Schmid I, Buendia MA, et al. A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients. Eur J Cancer. 2020;141:30\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.026","journal-title":"Eur J Cancer"},{"key":"2405_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.prp.2013.06.015","volume":"209","author":"WJ Yun","year":"2013","unstructured":"Yun WJ, Shin E, Lee K, Jung HY, Kim SH, Park YN, Yu E, Jang JJ. Clinicopathologic implication of hepatic progenitor cell marker expression in hepatoblastoma. Pathol Res Pract. 2013;209:568\u201373. https:\/\/doi.org\/10.1016\/j.prp.2013.06.015","journal-title":"Pathol Res Pract"},{"key":"2405_CR7","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1038\/s41467-021-25430-9","volume":"12","author":"G Nagae","year":"2021","unstructured":"Nagae G, Yamamoto S, Fujita M, Fujita T, Nonaka A, Umeda T, Fukuda S, Tatsuno K, Maejima K, Hayashi A, et al. Genetic and epigenetic basis of hepatoblastoma diversity. Nat Commun. 2021;12:5423. https:\/\/doi.org\/10.1038\/s41467-021-25430-9","journal-title":"Nat Commun"},{"key":"2405_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Grobner","year":"2018","unstructured":"Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555:321\u20137. https:\/\/doi.org\/10.1038\/nature25480","journal-title":"Nature"},{"key":"2405_CR9","first-page":"5007","volume":"55","author":"H Kurahashi","year":"1995","unstructured":"Kurahashi H, Takami K, Oue T, Kusafuka T, Okada A, Tawa A, Okada S, Nishisho I. Biallelic inactivation of the APC gene in hepatoblastoma. Cancer Res. 1995;55:5007\u201311.","journal-title":"Cancer Res"},{"key":"2405_CR10","first-page":"3320","volume":"56","author":"H Oda","year":"1996","unstructured":"Oda H, Imai Y, Nakatsuru Y, Hata J, Ishikawa T. Somatic mutations of the APC gene in sporadic hepatoblastomas. Cancer Res. 1996;56:3320\u20133.","journal-title":"Cancer Res"},{"key":"2405_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/(SICI)1098-2264(199908)25:4<399::AID-GCC14>3.0.CO;2-X","volume":"25","author":"H Blaker","year":"1999","unstructured":"Blaker H, Hofmann WJ, Rieker RJ, Penzel R, Graf M, Otto HF. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer. 1999;25:399\u2013402.","journal-title":"Genes Chromosomes Cancer"},{"key":"2405_CR12","first-page":"269","volume":"59","author":"A Koch","year":"1999","unstructured":"Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 1999;59:269\u201373.","journal-title":"Cancer Res"},{"key":"2405_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s0304-3835(99)00433-4","volume":"152","author":"YM Jeng","year":"2000","unstructured":"Jeng YM, Wu MZ, Mao TL, Chang MH, Hsu HC. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett. 2000;152:45\u201351. https:\/\/doi.org\/10.1016\/s0304-3835(99)00433-4","journal-title":"Cancer Lett"},{"key":"2405_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/sj.onc.1203356","volume":"19","author":"Y Wei","year":"2000","unstructured":"Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene. 2000;19:498\u2013504. https:\/\/doi.org\/10.1038\/sj.onc.1203356","journal-title":"Oncogene"},{"key":"2405_CR15","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1038\/sj.onc.1205591","volume":"21","author":"K Taniguchi","year":"2002","unstructured":"Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002;21:4863\u201371. https:\/\/doi.org\/10.1038\/sj.onc.1205591","journal-title":"Oncogene"},{"key":"2405_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/hep.28888","volume":"65","author":"P Sumazin","year":"2017","unstructured":"Sumazin P, Chen Y, Trevino LR, Sarabia SF, Hampton OA, Patel K, Mistretta TA, Zorman B, Thompson P, Heczey A, et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology. 2017;65:104\u201321. https:\/\/doi.org\/10.1002\/hep.28888","journal-title":"Hepatology"},{"key":"2405_CR17","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jhep.2014.08.009","volume":"61","author":"M Eichenmuller","year":"2014","unstructured":"Eichenmuller M, Trippel F, Kreuder M, Beck A, Schwarzmayr T, Haberle B, Cairo S, Leuschner I, von Schweinitz D, Strom TM, Kappler R. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol. 2014;61:1312\u201320. https:\/\/doi.org\/10.1016\/j.jhep.2014.08.009","journal-title":"J Hepatol"},{"key":"2405_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","volume":"14","author":"S Cairo","year":"2008","unstructured":"Cairo S, Armengol C, De Reynies A, Wei Y, Thomas E, Renard CA, Goga A, Balakrishnan A, Semeraro M, Gresh L, et al. Hepatic stem-like phenotype and interplay of Wnt\/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 2008;14:471\u201384. https:\/\/doi.org\/10.1016\/j.ccr.2008.11.002","journal-title":"Cancer Cell"},{"key":"2405_CR19","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/hep.27243","volume":"60","author":"D Jia","year":"2014","unstructured":"Jia D, Dong R, Jing Y, Xu D, Wang Q, Chen L, Li Q, Huang Y, Zhang Y, Zhang Z, et al. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology. 2014;60:1686\u201396. https:\/\/doi.org\/10.1002\/hep.27243","journal-title":"Hepatology"},{"key":"2405_CR20","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jhep.2014.09.016","volume":"61","author":"MA Buendia","year":"2014","unstructured":"Buendia MA. Unravelling the genetics of hepatoblastoma: few mutations, what else? J Hepatol. 2014;61:1202\u20134. https:\/\/doi.org\/10.1016\/j.jhep.2014.09.016","journal-title":"J Hepatol"},{"key":"2405_CR21","doi-asserted-by":"publisher","unstructured":"Sekiguchi M, Seki M, Kawai T, Yoshida K, Yoshida M, Isobe T, Hoshino N, Shirai R, Tanaka M, Souzaki R, et al. Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets. NPJ Precis Oncol. 2020;4. https:\/\/doi.org\/10.1038\/s41698-020-0125-y","DOI":"10.1038\/s41698-020-0125-y"},{"key":"2405_CR22","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1158\/2159-8290.CD-20-1809","volume":"11","author":"TZ Hirsch","year":"2021","unstructured":"Hirsch TZ, Pilet J, Morcrette G, Roehrig A, Monteiro BJE, Molina L, Bayard Q, Trepo E, Meunier L, Caruso S, et al. Integrated genomic analysis identifies driver genes and Cisplatin-Resistant progenitor phenotype in pediatric liver Cancer. Cancer Discov. 2021;11:2524\u201343. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1809","journal-title":"Cancer Discov"},{"key":"2405_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jhep.2020.03.025","volume":"73","author":"J Carrillo-Reixach","year":"2020","unstructured":"Carrillo-Reixach J, Torrens L, Simon-Coma M, Royo L, Domingo-Sabat M, Abril-Fornaguera J, Akers N, Sala M, Ragull S, Arnal M, et al. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. J Hepatol. 2020;73:328\u201341. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.025","journal-title":"J Hepatol"},{"key":"2405_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/pbc.24213","volume":"59","author":"GE Tomlinson","year":"2012","unstructured":"Tomlinson GE, Kappler R. Genetics and epigenetics of hepatoblastoma. Pediatr Blood Cancer. 2012;59:785\u201392. https:\/\/doi.org\/10.1002\/pbc.24213","journal-title":"Pediatr Blood Cancer"},{"key":"2405_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1055\/s-0040-1722645","volume":"41","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Solinas A, Cairo S, Evert M, Chen X, Calvisi DF. Molecular mechanisms of hepatoblastoma. Semin Liver Dis. 2021;41:28\u201341. https:\/\/doi.org\/10.1055\/s-0040-1722645","journal-title":"Semin Liver Dis"},{"key":"2405_CR26","doi-asserted-by":"publisher","first-page":"7122","DOI":"10.1038\/s41467-023-42418-9","volume":"14","author":"J Pilet","year":"2023","unstructured":"Pilet J, Hirsch TZ, Gupta B, Roehrig A, Morcrette G, Pire A, Letouze E, Fresneau B, Taque S, Brugieres L, et al. Preneoplastic liver colonization by 11p15.5 altered mosaic cells in young children with hepatoblastoma. Nat Commun. 2023;14:7122. https:\/\/doi.org\/10.1038\/s41467-023-42418-9","journal-title":"Nat Commun"},{"key":"2405_CR27","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1038\/s41467-023-43730-0","volume":"14","author":"AJ Murphy","year":"2023","unstructured":"Murphy AJ, Cheng C, Williams J, Shaw TI, Pinto EM, Dieseldorff-Jones K, Brzezinski J, Renfro LA, Tornwall B, Huff V, et al. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the children\u2019s oncology group AREN18B5-Q. Nat Commun. 2023;14:8006. https:\/\/doi.org\/10.1038\/s41467-023-43730-0","journal-title":"Nat Commun"},{"key":"2405_CR28","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1126\/science.aax1323","volume":"366","author":"THH Coorens","year":"2019","unstructured":"Coorens THH, Treger TD, Al-Saadi R, Moore L, Tran MGB, Mitchell TJ, Tugnait S, Thevanesan C, Young MD, Oliver TRW, et al. Embryonal precursors of Wilms tumor. Science. 2019;366:1247\u201351. https:\/\/doi.org\/10.1126\/science.aax1323","journal-title":"Science"},{"key":"2405_CR29","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/s0960-9822(00)00597-2","volume":"10","author":"C Kanduri","year":"2000","unstructured":"Kanduri C, Pant V, Loukinov D, Pugacheva E, Qi CF, Wolffe A, Ohlsson R, Lobanenkov VV. Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr Biol. 2000;10:853\u20136. https:\/\/doi.org\/10.1016\/s0960-9822(00)00597-2","journal-title":"Curr Biol"},{"key":"2405_CR30","first-page":"5041","volume":"54","author":"S Albrecht","year":"1994","unstructured":"Albrecht S, von Schweinitz D, Waha A, Kraus JA, von Deimling A, Pietsch T. Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. Cancer Res. 1994;54:5041\u20134.","journal-title":"Cancer Res"},{"key":"2405_CR31","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/BF01194272","volume":"120","author":"M Montagna","year":"1994","unstructured":"Montagna M, Menin C, Chieco-Bianchi L, D\u2019Andrea E. Occasional loss of constitutive heterozygosity at 11p15.5 and imprinting relaxation of the IGFII maternal allele in hepatoblastoma. J Cancer Res Clin Oncol. 1994;120:732\u20136. https:\/\/doi.org\/10.1007\/BF01194272","journal-title":"J Cancer Res Clin Oncol"},{"key":"2405_CR32","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0002-9440(10)64652-4","volume":"157","author":"W Hartmann","year":"2000","unstructured":"Hartmann W, Waha A, Koch A, Goodyer CG, Albrecht S, von Schweinitz D, Pietsch T. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. Am J Pathol. 2000;157:1393\u2013403. https:\/\/doi.org\/10.1016\/S0002-9440(10)64652-4","journal-title":"Am J Pathol"},{"key":"2405_CR33","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/ng0794-440","volume":"7","author":"T Moulton","year":"1994","unstructured":"Moulton T, Crenshaw T, Hao Y, Moosikasuwan J, Lin N, Dembitzer F, Hensle T, Weiss L, McMorrow L, Loew T, et al. Epigenetic lesions at the H19 locus in wilms\u2019 tumour patients. Nat Genet. 1994;7:440\u20137. https:\/\/doi.org\/10.1038\/ng0794-440","journal-title":"Nat Genet"},{"key":"2405_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/hmg\/ddl448","volume":"16","author":"A Sparago","year":"2007","unstructured":"Sparago A, Russo S, Cerrato F, Ferraiuolo S, Castorina P, Selicorni A, Schwienbacher C, Negrini M, Ferrero GB, Silengo MC, et al. Mechanisms causing imprinting defects in Familial Beckwith-Wiedemann syndrome with wilms\u2019 tumour. Hum Mol Genet. 2007;16:254\u201364. https:\/\/doi.org\/10.1093\/hmg\/ddl448","journal-title":"Hum Mol Genet"},{"key":"2405_CR35","doi-asserted-by":"publisher","unstructured":"Eggermann T, Maher ER, Kratz CP, Prawitt D. Molecular Basis of Beckwith-Wiedemann Syndrome Spectrum with Associated Tumors and Consequences for Clinical Practice. Cancers (Basel) 2022;14. https:\/\/doi.org\/10.3390\/cancers14133083","DOI":"10.3390\/cancers14133083"},{"key":"2405_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s42003-025-07961-9","volume":"8","author":"S Nirgude","year":"2025","unstructured":"Nirgude S, Tichy ED, Liu Z, Kavari SL, Pradieu RD, Byrne M, Yang F, Gil-de-Gomez L, Mamou B, Bernt KM, et al. Single-nucleus multiomic analysis of Beckwith-Wiedemann syndrome liver reveals PPARA signaling enrichment and metabolic dysfunction. Commun Biol. 2025;8:495. https:\/\/doi.org\/10.1038\/s42003-025-07961-9","journal-title":"Commun Biol"},{"key":"2405_CR37","first-page":"3245","volume":"61","author":"A Cadoret","year":"2001","unstructured":"Cadoret A, Ovejero C, Saadi-Kheddouci S, Souil E, Fabre M, Romagnolo B, Kahn A, Perret C. Hepatomegaly in Transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res. 2001;61:3245\u20139.","journal-title":"Cancer Res"},{"key":"2405_CR38","first-page":"1971","volume":"62","author":"N Harada","year":"2002","unstructured":"Harada N, Miyoshi H, Murai N, Oshima H, Tamai Y, Oshima M, Taketo MM. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res. 2002;62:1971\u20137.","journal-title":"Cancer Res"},{"key":"2405_CR39","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1038\/s41467-023-39717-6","volume":"14","author":"J Fang","year":"2023","unstructured":"Fang J, Singh S, Cheng C, Natarajan S, Sheppard H, Abu-Zaid A, Durbin AD, Lee HW, Wu Q, Steele J, et al. Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma. Nat Commun. 2023;14:4003. https:\/\/doi.org\/10.1038\/s41467-023-39717-6","journal-title":"Nat Commun"},{"key":"2405_CR40","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/gcc.23194","volume":"62","author":"A Vicha","year":"2023","unstructured":"Vicha A, Jencova P, Novakova-Kodetova D, Stolova L, Voriskova D, Vyletalova K, Broz P, Drahokoupilova E, Guha A, Kopecka M, Krskova L. Changes on chromosome 11p15.5 as specific marker for embryonal rhabdomyosarcoma? Genes Chromosomes Cancer. 2023;62:732\u20139. https:\/\/doi.org\/10.1002\/gcc.23194","journal-title":"Genes Chromosomes Cancer"},{"key":"2405_CR41","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1200\/JCO.2010.29.3837","volume":"29","author":"MH Malogolowkin","year":"2011","unstructured":"Malogolowkin MH, Katzenstein HM, Meyers RL, Krailo MD, Rowland JM, Haas J, Finegold MJ. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the children\u2019s oncology group. J Clin Oncol. 2011;29:3301\u20136. https:\/\/doi.org\/10.1200\/JCO.2010.29.3837","journal-title":"J Clin Oncol"},{"key":"2405_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jpedsurg.2022.05.022","volume":"57","author":"SA Vasudevan","year":"2022","unstructured":"Vasudevan SA, Meyers RL, Finegold MJ, Lopez-Terrada D, Ranganathan S, Dunn SP, Langham MR, McGahren ED, Tiao GM, Weldon CB, et al. Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: report from children\u2019s oncology group trial, AHEP0731. J Pediatr Surg. 2022;57:251\u20136. https:\/\/doi.org\/10.1016\/j.jpedsurg.2022.05.022","journal-title":"J Pediatr Surg"},{"key":"2405_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/hep.29672","volume":"68","author":"KB Hooks","year":"2018","unstructured":"Hooks KB, Audoux J, Fazli H, Lesjean S, Ernault T, Dugot-Senant N, Leste-Lasserre T, Hagedorn M, Rousseau B, Danet C, et al. New insights into diagnosis and therapeutic options for proliferative hepatoblastoma. Hepatology. 2018;68:89\u2013102. https:\/\/doi.org\/10.1002\/hep.29672","journal-title":"Hepatology"},{"key":"2405_CR44","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s42003-021-02562-8","volume":"4","author":"A Bondoc","year":"2021","unstructured":"Bondoc A, Glaser K, Jin K, Lake C, Cairo S, Geller J, Tiao G, Aronow B. Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma. Commun Biol. 2021;4:1049. https:\/\/doi.org\/10.1038\/s42003-021-02562-8","journal-title":"Commun Biol"},{"key":"2405_CR45","doi-asserted-by":"publisher","first-page":"10007","DOI":"10.1038\/s41467-024-53802-4","volume":"15","author":"PV Wu","year":"2024","unstructured":"Wu PV, Fish M, Hazard FK, Zhu C, Vennam S, Walton H, Wagh D, Coller J, Przybyl J, Morri M, et al. A developmental biliary lineage program cooperates with Wnt activation to promote cell proliferation in hepatoblastoma. Nat Commun. 2024;15:10007. https:\/\/doi.org\/10.1038\/s41467-024-53802-4","journal-title":"Nat Commun"},{"key":"2405_CR46","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1038\/s41467-022-32473-z","volume":"13","author":"H Song","year":"2022","unstructured":"Song H, Bucher S, Rosenberg K, Tsui M, Burhan D, Hoffman D, Cho SJ, Rangaswami A, Breese M, Leung S, et al. Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids. Nat Commun. 2022;13:4878. https:\/\/doi.org\/10.1038\/s41467-022-32473-z","journal-title":"Nat Commun"},{"key":"2405_CR47","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1002\/hep.32775","volume":"77","author":"H Huang","year":"2023","unstructured":"Huang H, Wu L, Lu L, Zhang Z, Qiu B, Mo J, Luo Y, Xi Z, Feng M, Wan P, et al. Single-cell transcriptomics uncovers cellular architecture and developmental trajectories in hepatoblastoma. Hepatology. 2023;77:1911\u201328. https:\/\/doi.org\/10.1002\/hep.32775","journal-title":"Hepatology"},{"key":"2405_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.01.031","author":"D Munter","year":"2025","unstructured":"Munter D, de Faria FW, Richter M, Aranda-Pardos I, Hotfilder M, Walter C, Paga E, Inserte C, Albert TK, Roy R, et al. Multiomic analysis uncovers a continuous spectrum of differentiation and Wnt-MDK-driven immune evasion in hepatoblastoma. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.01.031","journal-title":"J Hepatol"},{"key":"2405_CR49","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1038\/s41467-024-47280-x","volume":"15","author":"A Roehrig","year":"2024","unstructured":"Roehrig A, Hirsch TZ, Pire A, Morcrette G, Gupta B, Marcaillou C, Imbeaud S, Chardot C, Gonzales E, Jacquemin E, et al. Single-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma. Nat Commun. 2024;15:3031. https:\/\/doi.org\/10.1038\/s41467-024-47280-x","journal-title":"Nat Commun"},{"key":"2405_CR50","doi-asserted-by":"publisher","first-page":"e2203849119","DOI":"10.1073\/pnas.2203849119","volume":"119","author":"Y Jin","year":"2022","unstructured":"Jin Y, Anbarchian T, Wu P, Sarkar A, Fish M, Peng WC, Nusse R. Wnt signaling regulates hepatocyte cell division by a transcriptional repressor cascade. Proc Natl Acad Sci U S A. 2022;119:e2203849119. https:\/\/doi.org\/10.1073\/pnas.2203849119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2405_CR51","doi-asserted-by":"publisher","unstructured":"Sarkar A, Jin Y, DeFelice BC, Logan CY, Yang Y, Anbarchian T, Wu P, Morri M, Neff NF, Nguyen H, et al. Intermittent fasting induces rapid hepatocyte proliferation to restore the hepatostat in the mouse liver. Elife. 2023;12. https:\/\/doi.org\/10.7554\/eLife.82311","DOI":"10.7554\/eLife.82311"},{"key":"2405_CR52","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/hep.24702","volume":"55","author":"SJ Zweers","year":"2012","unstructured":"Zweers SJ, Booij KA, Komuta M, Roskams T, Gouma DJ, Jansen PL, Schaap FG. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology. 2012;55:575\u201383. https:\/\/doi.org\/10.1002\/hep.24702","journal-title":"Hepatology"},{"key":"2405_CR53","doi-asserted-by":"publisher","first-page":"8576","DOI":"10.1038\/s41467-024-52757-w","volume":"15","author":"TA Kluiver","year":"2024","unstructured":"Kluiver TA, Lu Y, Schubert SA, Kraaier LJ, Ringnalda F, Lijnzaad P, DeMartino J, Megchelenbrink WL, Amo-Addae V, Eising S, et al. Divergent WNT signaling and drug sensitivity profiles within hepatoblastoma tumors and organoids. Nat Commun. 2024;15:8576. https:\/\/doi.org\/10.1038\/s41467-024-52757-w","journal-title":"Nat Commun"},{"key":"2405_CR54","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jhep.2024.01.003","volume":"80","author":"AF Espinoza","year":"2024","unstructured":"Espinoza AF, Patel RH, Patel KR, Badachhape AA, Whitlock R, Srivastava RK, Govindu SR, Duong A, Kona A, Kureti P, et al. A novel treatment strategy utilizing Panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024;80:610\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.003","journal-title":"J Hepatol"},{"key":"2405_CR55","doi-asserted-by":"publisher","first-page":"e33870","DOI":"10.1371\/journal.pone.0033870","volume":"7","author":"C Yang","year":"2012","unstructured":"Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS ONE. 2012;7:e33870. https:\/\/doi.org\/10.1371\/journal.pone.0033870","journal-title":"PLoS ONE"},{"key":"2405_CR56","doi-asserted-by":"publisher","first-page":"101044","DOI":"10.1016\/j.xcrm.2023.101044","volume":"4","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xiang X, Chen H, Zhou L, Chen S, Zhang G, Liu X, Ren X, Liu J, Kuang M, et al. Intratumoral erythroblastic Islands restrain anti-tumor immunity in hepatoblastoma. Cell Rep Med. 2023;4:101044. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101044","journal-title":"Cell Rep Med"},{"key":"2405_CR57","doi-asserted-by":"publisher","first-page":"1145300","DOI":"10.3389\/fimmu.2023.1145300","volume":"14","author":"X Yu","year":"2023","unstructured":"Yu X, Xie L, Ge J, Li H, Zhong S, Liu X. Integrating single-cell RNA-seq and Spatial transcriptomics reveals MDK-NCL dependent immunosuppressive environment in endometrial carcinoma. Front Immunol. 2023;14:1145300. https:\/\/doi.org\/10.3389\/fimmu.2023.1145300","journal-title":"Front Immunol"},{"key":"2405_CR58","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/s41591-020-1073-3","volume":"26","author":"D Cerezo-Wallis","year":"2020","unstructured":"Cerezo-Wallis D, Contreras-Alcalde M, Troule K, Catena X, Mucientes C, Calvo TG, Canon E, Tejedo C, Pennacchi PC, Hogan S, et al. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nat Med. 2020;26:1865\u201377. https:\/\/doi.org\/10.1038\/s41591-020-1073-3","journal-title":"Nat Med"},{"key":"2405_CR59","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41420-023-01392-3","volume":"9","author":"L Ding","year":"2023","unstructured":"Ding L, Wang N, Wang Q, Fan X, Xin Y, Wang S. Midkine Inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration. Cell Death Discov. 2023;9:92. https:\/\/doi.org\/10.1038\/s41420-023-01392-3","journal-title":"Cell Death Discov"},{"key":"2405_CR60","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jhep.2021.06.023","volume":"75","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zuo C, Liu L, Hu Y, Yang B, Qiu S, Li Y, Cao D, Ju Z, Ge J, et al. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in erbb pathway-mutated gallbladder cancer. J Hepatol. 2021;75:1128\u201341. https:\/\/doi.org\/10.1016\/j.jhep.2021.06.023","journal-title":"J Hepatol"},{"key":"2405_CR61","doi-asserted-by":"publisher","first-page":"18254","DOI":"10.1038\/s41598-024-69183-z","volume":"14","author":"N Shi","year":"2024","unstructured":"Shi N, Chen S, Wang D, Wu T, Zhang N, Chen M, Ding X. MDK promotes M2 macrophage polarization to remodel the tumour microenvironment in clear cell renal cell carcinoma. Sci Rep. 2024;14:18254. https:\/\/doi.org\/10.1038\/s41598-024-69183-z","journal-title":"Sci Rep"},{"key":"2405_CR62","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-020-15770-3","volume":"11","author":"X Guo","year":"2020","unstructured":"Guo X, Pan Y, Xiong M, Sanapala S, Anastasaki C, Cobb O, Dahiya S, Gutmann DH. Midkine activation of CD8(+) T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth. Nat Commun. 2020;11:2177. https:\/\/doi.org\/10.1038\/s41467-020-15770-3","journal-title":"Nat Commun"},{"key":"2405_CR63","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/s41388-019-1124-8","volume":"39","author":"PS Filippou","year":"2020","unstructured":"Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020;39:2040\u201354. https:\/\/doi.org\/10.1038\/s41388-019-1124-8","journal-title":"Oncogene"},{"key":"2405_CR64","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","volume":"14","author":"J Zsiros","year":"2013","unstructured":"Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013;14:834\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(13)70272-9","journal-title":"Lancet Oncol"},{"key":"2405_CR65","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.1002\/cncr.24668","volume":"115","author":"MJ Sullivan","year":"2009","unstructured":"Sullivan MJ. Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears. Cancer. 2009;115:5623\u20136. https:\/\/doi.org\/10.1002\/cncr.24668","journal-title":"Cancer"},{"key":"2405_CR66","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1200\/JCO.2006.09.7204","volume":"26","author":"MH Malogolowkin","year":"2008","unstructured":"Malogolowkin MH, Katzenstein HM, Krailo M, Chen Z, Quinn JJ, Reynolds M, Ortega JA. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol. 2008;26:2379\u201383. https:\/\/doi.org\/10.1200\/JCO.2006.09.7204","journal-title":"J Clin Oncol"},{"key":"2405_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001280","author":"W Liao","year":"2025","unstructured":"Liao W, Zhang Y, Wang J, Cui G, Evert M, Xu M, Wu Y, Wang X, Deng S, Song X, et al. beta-Catenin regulates distinct pathways from YAP and suppresses ONECUT1 to drive hepatoblastoma development in mice and humans. Hepatology. 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001280","journal-title":"Hepatology"},{"key":"2405_CR68","doi-asserted-by":"publisher","first-page":"e29763","DOI":"10.1002\/pbc.29763","volume":"69","author":"JA Kahla","year":"2022","unstructured":"Kahla JA, Siegel DA, Dai S, Lupo PJ, Foster JH, Scheurer ME, Heczey AA. Incidence and 5-year survival of children and adolescents with hepatoblastoma in the united States. Pediatr Blood Cancer. 2022;69:e29763. https:\/\/doi.org\/10.1002\/pbc.29763","journal-title":"Pediatr Blood Cancer"},{"key":"2405_CR69","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/hep.28621","volume":"64","author":"D Nicolle","year":"2016","unstructured":"Nicolle D, Fabre M, Simon-Coma M, Gorse A, Kappler R, Nonell L, Mallo M, Haidar H, Deas O, Mussini C, et al. Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management. Hepatology. 2016;64:1121\u201335. https:\/\/doi.org\/10.1002\/hep.28621","journal-title":"Hepatology"},{"key":"2405_CR70","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/hep.31919","volume":"74","author":"ME Johnston","year":"2021","unstructured":"Johnston ME 2nd, Rivas MP, Nicolle D, Gorse A, Gulati R, Kumbaji M, Weirauch MT, Bondoc A, Cairo S, Geller J, et al. Olaparib inhibits tumor growth of hepatoblastoma in Patient-Derived xenograft models. Hepatology. 2021;74:2201\u201315. https:\/\/doi.org\/10.1002\/hep.31919","journal-title":"Hepatology"},{"key":"2405_CR71","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.18632\/oncotarget.27237","volume":"10","author":"D Kats","year":"2019","unstructured":"Kats D, Ricker CA, Berlow NE, Noblet B, Nicolle D, Mevel K, Branchereau S, Judde JG, Stiverson CD, Stiverson CL, et al. Volasertib preclinical activity in high-risk hepatoblastoma. Oncotarget. 2019;10:6403\u201317. https:\/\/doi.org\/10.18632\/oncotarget.27237","journal-title":"Oncotarget"},{"key":"2405_CR72","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3389\/fonc.2020.01138","volume":"10","author":"K Eloranta","year":"2020","unstructured":"Eloranta K, Cairo S, Liljestrom E, Soini T, Kyronlahti A, Judde JG, Wilson DB, Heikinheimo M, Pihlajoki M. Chloroquine triggers cell death and inhibits PARPs in cell models of aggressive hepatoblastoma. Front Oncol. 2020;10:1138. https:\/\/doi.org\/10.3389\/fonc.2020.01138","journal-title":"Front Oncol"},{"key":"2405_CR73","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jhep.2023.05.031","volume":"79","author":"A Claveria-Cabello","year":"2023","unstructured":"Claveria-Cabello A, Herranz JM, Latasa MU, Arechederra M, Uriarte I, Pineda-Lucena A, Prosper F, Berraondo P, Alonso C, Sangro B, et al. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. J Hepatol. 2023;79:989\u20131005. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.031","journal-title":"J Hepatol"},{"key":"2405_CR74","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s13046-024-03221-6","volume":"43","author":"S Demir","year":"2024","unstructured":"Demir S, Hotes A, Schmid T, Cairo S, Indersie E, Pisano C, Hiyama E, Hishiki T, Vokuhl C, Branchereau S, et al. Drug prioritization identifies Panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma. J Exp Clin Cancer Res. 2024;43:299. https:\/\/doi.org\/10.1186\/s13046-024-03221-6","journal-title":"J Exp Clin Cancer Res"},{"key":"2405_CR75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/HEP.0000000000000601","volume":"80","author":"M Failli","year":"2024","unstructured":"Failli M, Demir S, Rio-Alvarez D, Carrillo-Reixach A, Royo J, Domingo-Sabat L, Childs M, Maibach M, Alaggio R, Czauderna R, P., et al. Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with Pharmacological response. Hepatology. 2024;80:55\u201368. https:\/\/doi.org\/10.1097\/HEP.0000000000000601","journal-title":"Hepatology"},{"key":"2405_CR76","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/leu.2014.340","volume":"29","author":"W Fiskus","year":"2015","unstructured":"Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN. Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2015;29:1267\u201378. https:\/\/doi.org\/10.1038\/leu.2014.340","journal-title":"Leukemia"},{"key":"2405_CR77","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, Fleurence J, Sweidan R, Wang T, Zhang H, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637:940\u20136. https:\/\/doi.org\/10.1038\/s41586-024-08261-8","journal-title":"Nature"},{"key":"2405_CR78","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4390765\/v1","author":"J Yang","year":"2025","unstructured":"Yang J, Fang J, Singh S, Wells B, Wu Q, Jin H, Janke L, Wan S, Steele J, Connelly J, et al. The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells. Res Sq. 2025. https:\/\/doi.org\/10.21203\/rs.3.rs-4390765\/v1","journal-title":"Res Sq"},{"key":"2405_CR79","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ajpath.2019.02.002","volume":"189","author":"Q Min","year":"2019","unstructured":"Min Q, Molina L, Li J, Adebayo Michael AO, Russell JO, Preziosi ME, Singh S, Poddar M, Matz-Soja M, Ranganathan S, et al. beta-Catenin and Yes-Associated protein 1 cooperate in hepatoblastoma pathogenesis. Am J Pathol. 2019;189:1091\u2013104. https:\/\/doi.org\/10.1016\/j.ajpath.2019.02.002","journal-title":"Am J Pathol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02405-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02405-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02405-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:44:23Z","timestamp":1757256263000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02405-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2405"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02405-8","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Jun Yang is a subject Editor of British Journal of Cancer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}